Patents Assigned to PMV PHARMACEUTICALS, INC.
-
Patent number: 11963953Abstract: The compounds of the current disclosure include propynyl substituted indoles, where one or more hydrido radicals is substituted with a deuterium atom, wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant p53 protein.Type: GrantFiled: January 26, 2023Date of Patent: April 23, 2024Assignee: PMV Pharmaceuticals, Inc.Inventor: Binh Vu
-
Patent number: 11938124Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes methods of recovering wild-type function to p53 mutants by treating a cancer with a compound and a second agent. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used in combination with a secondary agent to reduce the progression of cancers that contain a p53 mutation.Type: GrantFiled: June 15, 2021Date of Patent: March 26, 2024Assignee: PMV Pharmaceuticals, Inc.Inventors: Arnold Levine, Melissa Dumble
-
Patent number: 11926632Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.Type: GrantFiled: June 21, 2021Date of Patent: March 12, 2024Assignee: PMV Pharmaceuticals, Inc.Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Yi Chen
-
Patent number: 11814373Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.Type: GrantFiled: September 22, 2020Date of Patent: November 14, 2023Assignee: PMV PHARMACEUTICALS, INC.Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Andrew Good
-
Patent number: 11807644Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.Type: GrantFiled: May 11, 2021Date of Patent: November 7, 2023Assignee: PMV PHARMACEUTICALS, INC.Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Andrew Good
-
Patent number: 11731953Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.Type: GrantFiled: June 22, 2021Date of Patent: August 22, 2023Assignee: PMV PHARMACEUTICALS, INC.Inventors: Binh Vu, Romyr Dominique, Hongju Li, Bruce Fahr, Yi Chen
-
Patent number: 11339141Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.Type: GrantFiled: March 16, 2020Date of Patent: May 24, 2022Assignee: PMV Pharmaceuticals, Inc.Inventors: Binh Vu, Romyr Dominique, Hongju Li
-
Patent number: 10640485Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.Type: GrantFiled: October 18, 2018Date of Patent: May 5, 2020Assignee: PMV PHARMACEUTICALS, INC.Inventors: Binh Vu, Romyr Dominique, Hongju Li